Investor desk
Investors should track partnership announcements, pipeline prioritization signals, and vendor consolidation themes emerging from EULAR 2026.
← Back to Events
Tier 1 Global Networking: High IMMUNOLOGY CONCLUDED
EULAR 2026 — Not specified, London, UK
The EULAR 2026 Congress will take place at the Excel London from Wednesday, 3 June to Saturday, 6 June 2026. Our organising committee have created a .
5,000+ Attendees
5 Presentations
3 Companies
2 Drugs
Presentation data updated Jun 5, 2026, 8:41 AM UTC
Why This Event Matters
The EULAR 2026 Congress will take place at the Excel London from Wednesday, 3 June to Saturday, 6 June 2026.
Industry impact
The EULAR 2026 Congress will take place at the Excel London from Wednesday, 3 June to Saturday, 6 June 2026.
Market implications
Expect signals on pricing, formulary strategy, and partnership economics relevant to immunology markets in the EU region.
Regulatory implications
EMA and national HTA frameworks are frequently debated at immunology industry gatherings.
Investor implications
Investors should track partnership announcements, pipeline prioritization signals, and vendor consolidation themes emerging from EULAR 2026.
Competitive implications
Competitive positioning among top immunology players and adjacent technology vendors is a core theme — compare outcomes with prior editions and peer conferences.
Event Significance
Tier-1 industry catalyst
50 /100 composite
EULAR 2026 is a targeted immunology forum where specialty pipeline readouts and BD conversations drive near-term positioning decisions. Primary driver: speaker calibre and KOL density.
- Media coverage 10/20
Moderate coverage; Nova editorial will prioritize confirmed data releases.
- Speaker quality 20/20
Plenary and late-breaker slots attract global KOLs — high signal for clinical and regulatory teams.
- Pipeline relevance 1/20
Early science or services-focused — lower near-term PDUFA linkage.
- Historical influence 13/20
Some historical catalysts; compare readouts against last cycle.
- Company participation 6/20
Smaller exhibitor set — focus on disclosed presenters rather than floor traffic.
Nova Pharma Intelligence · Analyst desk
Key Takeaways
- Watch oral (Amgen · inebilizumab): Phase 3 MITIGATE trial of UPLIZNA® (inebilizumab) in immunoglobulin G4-related disease (IgG4-RD): open-label extension d…
- Watch oral (Amgen): New Phase 3 MITIGATE Open-Label Extension Data Support ...
- Amgen carries 2 tracked presentations — map against peer readouts at EULAR 2026.
- UCB carries 1 tracked presentations — map against peer readouts at EULAR 2026.
- EMA and national HTA frameworks are frequently debated at immunology industry gatherings.
- inebilizumab (Amgen) — 1 data points on the schedule.
Timeline & Milestones
- Pre-event intelligence Complete
5 presentations tracked — Key Data and Companies hubs live.
- Conference opens Jun 3, 2026 Complete
Live readouts, late-breakers, and partnership announcements.
- Live coverage window Complete
1 Nova articles linked — see Coverage & Analysis.
- Conference closes Jun 6, 2026 Complete
Post-event recap, competitive takeaways, and trial updates.
Investors & analysts
Executive Summary
C-level briefThe EULAR 2026 Congress will take place at the Excel London from Wednesday, 3 June to Saturday, 6 June 2026.
Primary audience: Investors & analysts
Analyst Watch
Regulatory affairs
EMA and national HTA frameworks are frequently debated at immunology industry gatherings.
Competitive intelligence
Competitive positioning among top immunology players and adjacent technology vendors is a core theme — compare outcomes with prior editions and peer conferences.
Most Anticipated Presentations
Full data hub → ORAL
Phase 3 MITIGATE trial of UPLIZNA® (inebilizumab) in immunoglobulin G4-related disease (IgG4-RD): open-label extension data
ORAL Jun 3
OP0185
Treatment retention and clinical remission in 787 real-world patients with psoriatic arthritis treated with bimekizumab
ORAL Jun 3
Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio in complex high unmet need diseases
ORAL
Novartis data in polymyalgia rheumatica: efficacy and safety of novel therapy
Competitive Landscape
Company map →Competitive positioning among top immunology players and adjacent technology vendors is a core theme — compare outcomes with prior editions and peer conferences.
Companies to Watch
All companies →Drug Pipelines to Watch
Pipeline data →Coverage & Analysis
1 articlesRelated News & Research
Research hub →Event Intelligence Summary
Standalone summaries for EULAR 2026 — optimized for research and AI retrieval.
Executive Summary
The EULAR 2026 Congress will take place at the Excel London from Wednesday, 3 June to Saturday, 6 June 2026.
Analyst View
The EULAR 2026 Congress will take place at the Excel London from Wednesday, 3 June to Saturday, 6 June 2026.
Investor View
Investors should track partnership announcements, pipeline prioritization signals, and vendor consolidation themes emerging from EULAR 2026.
BD View
BD teams should prioritize networking with presenting companies and services vendors at EULAR 2026, focusing on immunology partnership and licensing opportunities.
Key Facts
- Event
- EULAR 2026
- Focus
- immunology
- Region
- Europe
- Attendance
- 5,000+
Ask Nova AI
AI-assisted answers grounded in NovaPharmaNews intelligence
Answers use retrieved site intelligence plus AI synthesis. Verify critical decisions with primary sources.
Frequently Asked Questions
What is EULAR 2026?
EULAR 2026 is a immunology industry conference bringing together executives, clinical leaders, and investors to discuss pipeline, regulatory, and commercial strategy.
Who attends EULAR 2026?
Typical attendees include pharma executives, BD teams, investors, regulatory affairs professionals, and clinical operations leaders focused on immunology.
Why is EULAR 2026 important?
EULAR 2026 influences partnership timing, pipeline prioritization, and policy debates that affect immunology markets for the next 12–18 months.
When is EULAR 2026?
EULAR 2026 takes place on the scheduled dates.
Where is EULAR 2026 held?
EULAR 2026 is held in the listed venue.
How many attendees does EULAR 2026 attract?
EULAR 2026 typically draws 5,000+ attendees from across the immunology ecosystem.
What companies participate at EULAR 2026?
3+ companies present data or participate in programming at EULAR 2026, spanning large pharma, biotech, and services vendors.
What should investors watch at EULAR 2026?
Investors should track partnership announcements, pipeline readouts, M&A signals, and management commentary on immunology catalysts during and after EULAR 2026.
What BD opportunities exist at EULAR 2026?
BD teams use EULAR 2026 for licensing discussions, co-development talks, and vendor selection across immunology — especially in networking sessions and satellite meetings.
How does EULAR 2026 compare with other pharma conferences?
EULAR 2026 is a tier-1 global congress for immunology — compare speaker quality, company participation, and historical deal flow with peer events in the same therapeutic or commercial vertical.
How do I get NovaPharmaNews coverage of EULAR 2026?
NovaPharmaNews publishes pre-event briefs, live coverage, and post-event analysis for EULAR 2026. Subscribe to event alerts on this page for breaking updates.